Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer

D. L. Lamm, A. P M Van der Meijden, A. Morales, S. A. Brosman, W. J. Catalona, H. W. Herr, M. S. Soloway, A. Steg, F. M J Debruyne

Research output: Contribution to journalArticle

558 Citations (Scopus)

Abstract

Intravesical therapy with bacillus Calmette-Guerin (BCG) has proved to be more effective in the prophylaxis and treatment of superficial bladder tumors and carcinoma in situ than most chemotherapeutic agents. Compared to intravesical chemotherapy, instillations with BCG provoke more local and systemic reactions. In addition to the commonly induced granulomatous inflammatory changes in the bladder, which produce irritative symptoms, this therapy may cause systemic side effects varying from mild malaise and fever to, in rare instances, life-threatening or fatal sepsis. We report the incidence and varieties of toxicities in 2,602 patients treated with intravesical BCG. Side effects are classified according to local and systemic toxicity. Treatment options vary according to the severity of toxicity from delaying or withholding instillations to treatment with antituberculous drugs for up to 6 months. In general, 95% of the patients have no serious side effects. Recognition of risk factors, particularly traumatic catheterization or concurrent cystitis, that result in systemic BCG absorption, as well as the prompt and appropriate treatment of early side effects should significantly decrease the incidence of severe toxicity.

Original languageEnglish
Pages (from-to)596-600
Number of pages5
JournalJournal of Urology
Volume147
Issue number3 I
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Incidence
Therapeutics
Intravesical Administration
Cystitis
Carcinoma in Situ
Catheterization
Sepsis
Urinary Bladder
Fever
Drug Therapy
Pharmaceutical Preparations

Keywords

  • BCG vaccine
  • bladder neoplasms
  • carcinoma in situ

ASJC Scopus subject areas

  • Urology

Cite this

Lamm, D. L., Van der Meijden, A. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W., ... Debruyne, F. M. J. (1992). Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. Journal of Urology, 147(3 I), 596-600.

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. / Lamm, D. L.; Van der Meijden, A. P M; Morales, A.; Brosman, S. A.; Catalona, W. J.; Herr, H. W.; Soloway, M. S.; Steg, A.; Debruyne, F. M J.

In: Journal of Urology, Vol. 147, No. 3 I, 01.01.1992, p. 596-600.

Research output: Contribution to journalArticle

Lamm, DL, Van der Meijden, APM, Morales, A, Brosman, SA, Catalona, WJ, Herr, HW, Soloway, MS, Steg, A & Debruyne, FMJ 1992, 'Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer', Journal of Urology, vol. 147, no. 3 I, pp. 596-600.
Lamm DL, Van der Meijden APM, Morales A, Brosman SA, Catalona WJ, Herr HW et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. Journal of Urology. 1992 Jan 1;147(3 I):596-600.
Lamm, D. L. ; Van der Meijden, A. P M ; Morales, A. ; Brosman, S. A. ; Catalona, W. J. ; Herr, H. W. ; Soloway, M. S. ; Steg, A. ; Debruyne, F. M J. / Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. In: Journal of Urology. 1992 ; Vol. 147, No. 3 I. pp. 596-600.
@article{9e2aeddcca224d7dbf4d86bcd2935ab9,
title = "Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer",
abstract = "Intravesical therapy with bacillus Calmette-Guerin (BCG) has proved to be more effective in the prophylaxis and treatment of superficial bladder tumors and carcinoma in situ than most chemotherapeutic agents. Compared to intravesical chemotherapy, instillations with BCG provoke more local and systemic reactions. In addition to the commonly induced granulomatous inflammatory changes in the bladder, which produce irritative symptoms, this therapy may cause systemic side effects varying from mild malaise and fever to, in rare instances, life-threatening or fatal sepsis. We report the incidence and varieties of toxicities in 2,602 patients treated with intravesical BCG. Side effects are classified according to local and systemic toxicity. Treatment options vary according to the severity of toxicity from delaying or withholding instillations to treatment with antituberculous drugs for up to 6 months. In general, 95{\%} of the patients have no serious side effects. Recognition of risk factors, particularly traumatic catheterization or concurrent cystitis, that result in systemic BCG absorption, as well as the prompt and appropriate treatment of early side effects should significantly decrease the incidence of severe toxicity.",
keywords = "BCG vaccine, bladder neoplasms, carcinoma in situ",
author = "Lamm, {D. L.} and {Van der Meijden}, {A. P M} and A. Morales and Brosman, {S. A.} and Catalona, {W. J.} and Herr, {H. W.} and Soloway, {M. S.} and A. Steg and Debruyne, {F. M J}",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "147",
pages = "596--600",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3 I",

}

TY - JOUR

T1 - Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer

AU - Lamm, D. L.

AU - Van der Meijden, A. P M

AU - Morales, A.

AU - Brosman, S. A.

AU - Catalona, W. J.

AU - Herr, H. W.

AU - Soloway, M. S.

AU - Steg, A.

AU - Debruyne, F. M J

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Intravesical therapy with bacillus Calmette-Guerin (BCG) has proved to be more effective in the prophylaxis and treatment of superficial bladder tumors and carcinoma in situ than most chemotherapeutic agents. Compared to intravesical chemotherapy, instillations with BCG provoke more local and systemic reactions. In addition to the commonly induced granulomatous inflammatory changes in the bladder, which produce irritative symptoms, this therapy may cause systemic side effects varying from mild malaise and fever to, in rare instances, life-threatening or fatal sepsis. We report the incidence and varieties of toxicities in 2,602 patients treated with intravesical BCG. Side effects are classified according to local and systemic toxicity. Treatment options vary according to the severity of toxicity from delaying or withholding instillations to treatment with antituberculous drugs for up to 6 months. In general, 95% of the patients have no serious side effects. Recognition of risk factors, particularly traumatic catheterization or concurrent cystitis, that result in systemic BCG absorption, as well as the prompt and appropriate treatment of early side effects should significantly decrease the incidence of severe toxicity.

AB - Intravesical therapy with bacillus Calmette-Guerin (BCG) has proved to be more effective in the prophylaxis and treatment of superficial bladder tumors and carcinoma in situ than most chemotherapeutic agents. Compared to intravesical chemotherapy, instillations with BCG provoke more local and systemic reactions. In addition to the commonly induced granulomatous inflammatory changes in the bladder, which produce irritative symptoms, this therapy may cause systemic side effects varying from mild malaise and fever to, in rare instances, life-threatening or fatal sepsis. We report the incidence and varieties of toxicities in 2,602 patients treated with intravesical BCG. Side effects are classified according to local and systemic toxicity. Treatment options vary according to the severity of toxicity from delaying or withholding instillations to treatment with antituberculous drugs for up to 6 months. In general, 95% of the patients have no serious side effects. Recognition of risk factors, particularly traumatic catheterization or concurrent cystitis, that result in systemic BCG absorption, as well as the prompt and appropriate treatment of early side effects should significantly decrease the incidence of severe toxicity.

KW - BCG vaccine

KW - bladder neoplasms

KW - carcinoma in situ

UR - http://www.scopus.com/inward/record.url?scp=0026578493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026578493&partnerID=8YFLogxK

M3 - Article

VL - 147

SP - 596

EP - 600

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3 I

ER -